|
|
Article: Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results.(Financial report)
- Article from:
- Blood Weekly
- Article date:
- November 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, reported its consolidated financial results for the third quarter ended September 30, 2009 and company highlights (see also Alnylam Pharmaceuticals, Inc.).
"Activities this quarter reflect the substantial progress we are making as we continue to lead the industry's efforts in the discovery and development of RNAi therapeutics," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "We are advancing our clinical pipeline and are on track with our goal to have three clinical-stage programs by the end of the year, with our planned IND filing for our ALN-TTR program. We are ...